"I love Enterome - Microbiome decoded ∙ Healthcare transformed"

2022-09-11 22:43:56

AboutAbout usLeadershipPartnersInvestorsPipelinePipelineOncoMimics™EndoMimics™AllerMimics™Partnered ProductsPlatformOur Mimicry ApproachOur Drug Discovery PlatformClinical TrialsGlioblastomaAdrenal tumorsB cell malignanciesCrohn’s DiseaseNews & EventsPress ReleasesEventsPresentations & PostersRelevant LiteratureCareersOur ValuesCareers Microbiome decoded ∙ Healthcare transformed We are a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on our unique ability to de-code the gut microbiome’s interaction with the immune system.Our Mimicry drug discovery platform provides us with an unrivalled ability to identify and produce microbiome-derived small protein and peptide drug candidates.The Mimicry platform has allowed us to develop our core, proprietary highly promising OncoMimics™ pipeline which has generated distinct, first-in-class clinical candidates targeting cancer. Watch our video hereWe have also developed two further pipelines, EndoMimics™ and AllerMimics™, targeting inflammatory diseases and food allergies respectively. These pipelines are being co-developed in partnership with Nestlé Health Science. We are a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on our unique ability to de-code the gut microbiome’s interaction with the immune system.Our Mimicry drug discovery platform provides us with an unrivalled ability to identify and produce microbiome-derived small protein and peptide drug candidates.The Mimicry platform has allowed us to develop our core, proprietary highly promising OncoMimics™ pipeline which has generated distinct, first-in-class clinical candidates targeting cancer. Watch our video hereWe have also developed two further pipelines, EndoMimics™ and AllerMimics™, targeting inflammatory diseases and food allergies respectively. These pipelines are being co-developed in partnership with Nestlé Health Science. Microbiome Decoded Database of 20+ millions unique full length and functional proteins from the gut microbiome Specifically designed Mimicry drug discovery platform to decipher this database Three transformative drug pipelines targeting cancer, inflammatory diseases and allergies A new class of therapeutics poised to improve human health Healthcare transformed Featured News 06 September 2022 Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022 Read More 18 July 2022 Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease Read More 06 June 2022 Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022 Read More Contact us Enterome France Headquarters94/96 avenue Ledru-Rollin 75011 Paris – FranceTel: +33 (0)1 75 77 27 85 Lab facilitiesBiocluster Genopole5 rue Henri Desbruères – 91030 Evry Cedex AboutAbout usLeadershipPartnersInvestorsPipelinePipelineOncoMimics™EndoMimics™AllerMimics™Partnered ProductsPlatformOur Mimicry ApproachOur Drug Discovery PlatformClinical TrialsGlioblastomaAdrenal tumorsB cell malignanciesCrohn’s DiseaseNews & EventsPress ReleasesEventsPresentations & PostersRelevant LiteratureCareersOur ValuesCareers